(NASDAQ: BDSX) Biodesix's forecast annual revenue growth rate of 14.77% is forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 8.15%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 15.53%.
Biodesix's revenue in 2026 is $102,939,000.On average, 9 Wall Street analysts forecast BDSX's revenue for 2026 to be $1,194,597,580, with the lowest BDSX revenue forecast at $1,140,470,345, and the highest BDSX revenue forecast at $1,235,324,895. On average, 9 Wall Street analysts forecast BDSX's revenue for 2027 to be $1,429,148,933, with the lowest BDSX revenue forecast at $1,354,235,995, and the highest BDSX revenue forecast at $1,496,781,599.
In 2028, BDSX is forecast to generate $1,668,870,334 in revenue, with the lowest revenue forecast at $1,588,259,793 and the highest revenue forecast at $1,745,999,007.